Treatment options in patients with localized gastric cancer

Abstract

Lokalize mide kanserli hastalarda tedavi seçenekleri

Öz

Mide kanseri tüm dünyada hala en ölümcül kanserlerden biridir. Opere mide kanserinde nüks oranın yüksek olması perioperatif ve postoperatif tedavilerin gerekliliğini ortaya koymaktadır. Son yıllarda perioperatif tedavi seçenekleri ile sağ kalımlarda belirgin artış gözlenmiştir. Bu derleme, lokalize mide kanserli hastalarda tedavi seçeneklerini değerlendirmek ve en iyi tedavi seçeneğini belirlemek amacıyla yapılmıştır.

Anahtar Kelimeler

• mide kanseri
• postoperatif
• preoperatif
• kemoterapi
• adjuvan radyoterapi

References

1. 1.Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394-424.
2. 2.Sexton RE, Al Hallak MN, Diab M, Azmi AS. Gastric cancer: a comprehensive review of current and future treatment strategies. Cancer Metastasis Rev. 2020;39(4):1179-203.
3. 3.Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355(1):11-20.
4. 4.Elimova E, Janjigian YY, Mulcahy M, Catenacci DV, Blum MA, Almhanna K, et al. It Is Time to Stop Using Epirubicin to Treat Any Patient With Gastroesophageal Adenocarcinoma. J Clin Oncol. 2017;35(4):475-477.
5. 5.Ychou M, Boige V, Pignon JP, Conroy T, Bouche O, Lebreton G, et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol. 2011;29(13):1715-1721.
6. 6.Al-Batran SE, Homann N, Pauligk C, Goetze TO, Meiler J, Kasper S, et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet. 2019;393(10184):1948-1957.
7. 7.Bang YJ, Kim YW, Yang HK, Chung HC, Park YK, Lee KH, et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet. 2012;379(9813):315-321.
8. 8.MacDonald JS, Smalley SR, Benedetti J, et al. Chemo-radiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Eng J Med 2001;345:725-730.

9. 9.Sasako M, Sakuramoto S, Katai H, Kinoshita T, Furukawa H, Yamaguchi T, et al. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer (ACTS-GS study). J Clin Oncol. 2011;29(33):4387-4393.
10. 10.Dikken JL, Jansen EP, Cats A, Bakker B, Hartgrink HH, Kranenbarg EM, et al. Impact of the extent of surgery and postoperative chemoradiotherapy on recurrence patterns in gastric cancer. J Clin Oncol. 2010;28(14):2430-2436.
11. 11. Lee J, Lim DH, Kim S, Park SH, Park JO, Park YS, et al. Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial. J Clin Oncol. 2012;30(3):268-273.